The team anticipates launching its first clinical diagnostic assay, which will detect targeted, low-frequency genetic mutations in lung cancer, in 2021.
The researchers will use Agilent's Fourier-transform infrared spectroscopy technology to monitor infants and determine those at highest risk of developing atopic eczema.
Clinicians can use the PD-L1 IHC 22C3 pharmDx assay to help identify head and neck squamous cell carcinoma patients for treatment with Merck's Keytruda in Europe.
Due out in December, the Magnis automated library prep instrument is meant to be an affordable and easy way for researchers to use Agilent's SureSelect kits.
